Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the hepatic manifestations of the metabolic syndrome. Since the prevalence of obesity and consequently of the metabolic syndrome is steadily increasing, the different types of NAFLD are nowadays the most common cause of liver injury in North America. The development of NASH and fatty liver cirrhosis occurs af...

ABSTRACT Non-alcoholic fatty liver disease is a very common medical condition, driven by combination of genetic and lifestyle factors, ultimately producing severe chronic increased cardiovascular risk. Most people are asymptomatic for long time, their daily life unaffected, leading to difficulty in identifying managing who slowly progress non-alcoholic steatohepatitis (NASH), NASH-cirrhosis, ev...

Non-alcoholic fatty liver disease is the most prevalent with a global prevalence of 25%. The frequency non-alcoholic and percentage people severe are expected to rise given ongoing obesity pandemic, in diabetes, other factors. This will have significant effect on health care expenditure need for transplantation, which steatohepatitis already track overtake alcoholic as reason. characterized by ...

......................................... Received: 11-02-14 Accepted: 21-02-14 Abstract In a normal human liver 5% of its mass consists of lipids. When deposition of fat increases, the terms most often used are fatty liver or steatosis. This includes non-alcoholic fatty liver disease whose acronym is NAFLD and alcoholic liver disease (ALD). A liver biopsy is still considered to be the gold sta...

Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invas...